XERS

Xeris Biopharma Holdings

• Seeking Alpha·3d ago

  Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity

• Dow Jones·3d ago

  Xeris Biopharma Is Maintained at Overweight by Barclays

• Benzinga·3d ago

  Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

• TipRanks·3d ago

  Xeris Biopharma price target raised to $12 from $9 at Barclays

• TipRanks·3d ago

  Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS) and BioNTech SE (BNTX)

• Simply Wall St·4d ago

  Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses

• Simply Wall St·5d ago

  Xeris Biopharma Holdings (XERS) Could Be 23% Undervalued As Guidance Tightens And Pipeline Progress Continues

• Simply Wall St·08/13 17:07

  Mission Produce And Two Other Stocks Estimated To Be Trading Below Intrinsic Value

• Simply Wall St·08/10 10:33

  Xeris Biopharma’s Rising Revenue And Wider Losses Could Be A Game Changer For XERS

• Simply Wall St·08/09 02:41

  Should Xeris Biopharma Holdings (XERS) Be Revalued After Strong Q2 Revenue And Fresh Guidance?

• Simply Wall St·08/07 22:37

  Xeris Biopharma (XERS) Stock Jumps On Record Revenue Despite Wider Losses

• TipRanks·08/07 12:10

  Piper Sandler Sticks to Its Hold Rating for Xeris Pharmaceuticals (XERS)

• TipRanks·08/07 00:12

  Xeris Pharmaceuticals’ Earnings Call Highlights Growth Momentum

• TipRanks·08/06 11:17

  Xeris Biopharma tightens FY26 revnue view $385M-$390M, consensus $385.94M

• Benzinga·08/06 11:11

  Xeris Biopharma Holdings Q2 EPS $(0.18) Misses $0.00 Estimate, Sales $92.100M Beat $90.225M Estimate